Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.23
SYK's Cash to Debt is ranked higher than
65% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. SYK: 1.23 )
SYK' s 10-Year Cash to Debt Range
Min: 0.04   Max: 164.16
Current: 1.23

0.04
164.16
Equity to Asset 0.52
SYK's Equity to Asset is ranked higher than
60% of the 375 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. SYK: 0.52 )
SYK' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.78
Current: 0.52

0.22
0.78
F-Score: 4
Z-Score: 3.96
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.78
SYK's Operating margin (%) is ranked higher than
81% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. SYK: 9.78 )
SYK' s 10-Year Operating margin (%) Range
Min: -5.63   Max: 23.92
Current: 9.78

-5.63
23.92
Net-margin (%) 7.40
SYK's Net-margin (%) is ranked higher than
80% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.13 vs. SYK: 7.40 )
SYK' s 10-Year Net-margin (%) Range
Min: 0.92   Max: 17.39
Current: 7.4

0.92
17.39
ROE (%) 7.73
SYK's ROE (%) is ranked higher than
76% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. SYK: 7.73 )
SYK' s 10-Year ROE (%) Range
Min: 2.89   Max: 28.97
Current: 7.73

2.89
28.97
ROA (%) 4.38
SYK's ROA (%) is ranked higher than
76% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. SYK: 4.38 )
SYK' s 10-Year ROA (%) Range
Min: 0.71   Max: 15.38
Current: 4.38

0.71
15.38
ROC (Joel Greenblatt) (%) 32.04
SYK's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.84 vs. SYK: 32.04 )
SYK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12.96   Max: 71.6
Current: 32.04

-12.96
71.6
Revenue Growth (%) 8.80
SYK's Revenue Growth (%) is ranked higher than
83% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. SYK: 8.80 )
SYK' s 10-Year Revenue Growth (%) Range
Min: 7.6   Max: 32.9
Current: 8.8

7.6
32.9
EBITDA Growth (%) -9.60
SYK's EBITDA Growth (%) is ranked higher than
67% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.20 vs. SYK: -9.60 )
SYK' s 10-Year EBITDA Growth (%) Range
Min: -9.6   Max: 59.4
Current: -9.6

-9.6
59.4
EPS Growth (%) -6.20
SYK's EPS Growth (%) is ranked higher than
69% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. SYK: -6.20 )
SYK' s 10-Year EPS Growth (%) Range
Min: -43   Max: 153
Current: -6.2

-43
153
» SYK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SYK Guru Trades in Q3 2013

Jeremy Grantham 2,296,002 sh (+42.22%)
Jim Simons 86,500 sh (+37.08%)
Joel Greenblatt 112,529 sh (+34.91%)
Chuck Royce 113,800 sh (+11.57%)
Robert Olstein 108,000 sh (unchged)
Yacktman Focused Fund 5,100,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Fund 4,900,000 sh (unchged)
Donald Yacktman 11,986,101 sh (-0.85%)
Ken Fisher 8,000 sh (-4.42%)
Ray Dalio 16,567 sh (-27.97%)
Steven Cohen 31,611 sh (-28.1%)
Paul Tudor Jones 8,900 sh (-93.12%)
» More
Q4 2013

SYK Guru Trades in Q4 2013

George Soros 450,000 sh (New)
Jim Simons 350,400 sh (+305.09%)
Ken Fisher 19,889 sh (+148.61%)
Paul Tudor Jones 13,610 sh (+52.92%)
Jeremy Grantham 2,636,722 sh (+14.84%)
Robert Olstein 108,000 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Fund 4,900,000 sh (unchged)
Yacktman Focused Fund 5,100,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Donald Yacktman 11,957,213 sh (-0.24%)
Chuck Royce 112,500 sh (-1.14%)
Steven Cohen 27,272 sh (-13.73%)
Ray Dalio 13,567 sh (-18.11%)
Joel Greenblatt 6,852 sh (-93.91%)
» More
Q1 2014

SYK Guru Trades in Q1 2014

George Soros 1,098,618 sh (+144.14%)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Fund 4,900,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Jim Simons Sold Out
Donald Yacktman 11,592,319 sh (-3.05%)
Robert Olstein 104,000 sh (-3.7%)
Yacktman Focused Fund 4,800,000 sh (-5.88%)
Jeremy Grantham 2,472,702 sh (-6.22%)
Chuck Royce 104,800 sh (-6.84%)
Ray Dalio 11,667 sh (-14%)
Paul Tudor Jones 5,600 sh (-58.85%)
Joel Greenblatt 2,788 sh (-59.31%)
Steven Cohen 5,156 sh (-81.09%)
Ken Fisher 3,410 sh (-82.85%)
» More
Q2 2014

SYK Guru Trades in Q2 2014

Jim Simons 38,800 sh (New)
Mario Gabelli 20,100 sh (New)
George Soros 1,678,108 sh (+52.75%)
Paul Tudor Jones 7,777 sh (+38.88%)
Vanguard Health Care Fund 1,433,500 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Ken Fisher 3,320 sh (-2.64%)
Robert Olstein 98,000 sh (-5.77%)
Yacktman Fund 4,613,000 sh (-5.86%)
Donald Yacktman 10,178,928 sh (-12.19%)
Chuck Royce 92,000 sh (-12.21%)
Jeremy Grantham 2,047,202 sh (-17.21%)
Yacktman Focused Fund 3,830,000 sh (-20.21%)
» More
» Details

Insider Trades

Latest Guru Trades with SYK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Yacktman Focused Fund 2014-06-30 Reduce -20.21%0.83%$76.72 - $86.08 $ 82.141%3830000
Donald Yacktman 2014-06-30 Reduce -12.19%0.48%$76.72 - $86.08 $ 82.141%10178928
George Soros 2014-06-30 Add 52.75%0.38%$76.72 - $86.08 $ 82.141%1678108
Yacktman Fund 2014-06-30 Reduce -5.86%0.21%$76.72 - $86.08 $ 82.141%4613000
Ray Dalio 2014-06-30 Sold Out 0.01%$76.72 - $86.08 $ 82.141%0
Mario Gabelli 2014-06-30 New Buy0.01%$76.72 - $86.08 $ 82.141%20100
Joel Greenblatt 2014-06-30 Sold Out $76.72 - $86.08 $ 82.141%0
George Soros 2014-03-31 Add 144.14%0.52%$74.63 - $83.35 $ 82.144%1098618
Yacktman Focused Fund 2014-03-31 Reduce -5.88%0.24%$74.63 - $83.35 $ 82.144%4800000
Donald Yacktman 2014-03-31 Reduce -3.05%0.11%$74.63 - $83.35 $ 82.144%11592319
Joel Greenblatt 2014-03-31 Reduce -59.31%0.01%$74.63 - $83.35 $ 82.144%2788
George Soros 2013-12-31 New Buy0.29%$67.34 - $75.39 $ 82.1412%450000
Joel Greenblatt 2013-12-31 Reduce -93.91%0.23%$67.34 - $75.39 $ 82.1412%6852
Joel Greenblatt 2013-09-30 Add 34.91%0.06%$64.2 - $71.78 $ 82.1419%112529
Ray Dalio 2013-09-30 Reduce -27.97%$64.2 - $71.78 $ 82.1419%16567
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 45.70
SYK's P/E(ttm) is ranked higher than
75% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 60.80 vs. SYK: 45.70 )
SYK' s 10-Year P/E(ttm) Range
Min: 11.31   Max: 48.82
Current: 45.7

11.31
48.82
P/B 3.50
SYK's P/B is ranked higher than
68% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. SYK: 3.50 )
SYK' s 10-Year P/B Range
Min: 2.19   Max: 9.09
Current: 3.5

2.19
9.09
P/S 3.40
SYK's P/S is ranked higher than
67% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. SYK: 3.40 )
SYK' s 10-Year P/S Range
Min: 1.93   Max: 5.98
Current: 3.4

1.93
5.98
PFCF 18.90
SYK's PFCF is ranked higher than
92% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SYK: 18.90 )
SYK' s 10-Year PFCF Range
Min: 11.63   Max: 65.41
Current: 18.9

11.63
65.41
EV-to-EBIT 33.29
SYK's EV-to-EBIT is ranked higher than
75% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 38.19 vs. SYK: 33.29 )
SYK' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 35.3
Current: 33.29

6.8
35.3
Shiller P/E 26.60
SYK's Shiller P/E is ranked higher than
90% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SYK: 26.60 )
SYK' s 10-Year Shiller P/E Range
Min: 15.93   Max: 80.88
Current: 26.6

15.93
80.88
Current Ratio 2.53
SYK's Current Ratio is ranked higher than
69% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. SYK: 2.53 )
SYK' s 10-Year Current Ratio Range
Min: 1.61   Max: 5.37
Current: 2.53

1.61
5.37
Quick Ratio 2.10
SYK's Quick Ratio is ranked higher than
72% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. SYK: 2.10 )
SYK' s 10-Year Quick Ratio Range
Min: 0.98   Max: 4.63
Current: 2.1

0.98
4.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
SYK's Dividend Yield is ranked higher than
60% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. SYK: 1.40 )
SYK' s 10-Year Dividend Yield Range
Min: 0.15   Max: 1.66
Current: 1.4

0.15
1.66
Dividend Payout 0.66
SYK's Dividend Payout is ranked higher than
86% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SYK: 0.66 )
SYK' s 10-Year Dividend Payout Range
Min: 0.18   Max: 1.69
Current: 0.66

0.18
1.69
Dividend growth (3y) 20.40
SYK's Dividend growth (3y) is ranked higher than
87% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 10.10 vs. SYK: 20.40 )
SYK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 81.9
Current: 20.4

0
81.9
Yield on cost (5-Year) 12.28
SYK's Yield on cost (5-Year) is ranked higher than
99% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 1.38 vs. SYK: 12.28 )
SYK' s 10-Year Yield on cost (5-Year) Range
Min: 1.32   Max: 14.57
Current: 12.28

1.32
14.57
Share Buyback Rate 1.50
SYK's Share Buyback Rate is ranked higher than
93% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. SYK: 1.50 )
SYK' s 10-Year Share Buyback Rate Range
Min: 2   Max: -3.2
Current: 1.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.00
SYK's Price/Tangible Book is ranked higher than
58% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. SYK: 11.00 )
SYK' s 10-Year Price/Tangible Book Range
Min: 2.87   Max: 632.38
Current: 11

2.87
632.38
Price/DCF (Projected) 1.50
SYK's Price/DCF (Projected) is ranked higher than
90% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 27.67 vs. SYK: 1.50 )
SYK' s 10-Year Price/DCF (Projected) Range
Min: 0.92   Max: 112.25
Current: 1.5

0.92
112.25
Price/Median PS Value 1.00
SYK's Price/Median PS Value is ranked higher than
79% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.19 vs. SYK: 1.00 )
SYK' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.75
Current: 1

0.62
1.75
Price/Graham Number 4.70
SYK's Price/Graham Number is ranked higher than
73% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 6.52 vs. SYK: 4.70 )
SYK' s 10-Year Price/Graham Number Range
Min: 1.23   Max: 36.14
Current: 4.7

1.23
36.14
Earnings Yield (Greenblatt) 3.00
SYK's Earnings Yield (Greenblatt) is ranked higher than
61% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. SYK: 3.00 )
SYK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.8   Max: 14.6
Current: 3

2.8
14.6
Forward Rate of Return (Yacktman) -3.51
SYK's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 1.19 vs. SYK: -3.51 )
SYK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3   Max: 38.5
Current: -3.51

-3
38.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SMA, ZMH, STJ, EW » details
Traded in other countries:SYK.Germany
Stryker Corporation was incorporated in Michigan in 1946 as the successor company to a business founded in 1941. It is a medical technology company. The Company's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties. The Company's three reportable business segments are Reconstructive, MedSurg, and Neurotechnology and Spine. The Reconstructive segment includes orthopaedic reconstructive (hip and knee) and trauma implant systems as well as other related products. The MedSurg segment include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); reprocessed and remanufactured medical devices; as well as other medical device products used in a variety of medical specialties. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's neurotechnology and Spine products include a comprehensive portfolio of products including both neurosurgical and neurovascular devices. Its neurotechnology offering includes products used for minimally invasive endovascular techniques, as well as a comprehensive line of products for traditional brain and open skull base surgical procedures, orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products, as well as minimally invasive products for the treatment of acute ischemic stroke. The Company also develops, manufactures and markets spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. In the United States, most of the Company's products are marketed directly to doctors, hospitals and other health-care facilities. The Company's main competitors in neurotechnology are Covidien and Micrus Endovascular, LLC and in spine products are Medtronic Sofamor Danek, Inc., and DePuy Spine, Inc. The Company's businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.
» More Articles for SYK

Headlines

Articles On GuruFocus.com
Pain Relief and Profits Jul 27 2014 
Companies That Give Shareholders a Raise Feb 14 2014 
Ken Fisher’s Top Increases of the Fourth Quarter Jan 15 2014 
Stocks with the Greatest Net Guru Buying in Q2 Sep 09 2013 
Forecasting Future Earnings Is the Key to Successful Stock Investing, Consensus Analysts’ Estimate Mar 14 2013 
Solid but expensive Feb 23 2013 
comment on SYK Feb 04 2013 
Donald Yacktman Buys Dell Inc, Stryker, Coca-Cola, IBM, Sells Research in Motion, H&R Block Feb 02 2013 
Yacktman Fund Buys Dell Inc, Stryker Corporation, Coca-cola Co, Sells H&R Block Inc, Research In Mot Jan 29 2013 
Stryker Corporation (SYK) Dividend Stock Analysis Jan 11 2013 

More From Our Partners
Morgan Stanley Remains Positive On Stryker Corporation Sep 18 2014 - BENZINGA

More From Other Websites
[video] U.S. Tax-Switch Clampdown Scares European Equity Investors as Indices Tumble Sep 23 2014
Stryker to Host Conference Call on October 16, 2014 Sep 08 2014
Stryker Grows via Acquisitions but M&A Deals Pose Risk Sep 05 2014
Pricey Stryker Needs a Deal to Spur Healthy Growth Sep 04 2014
STRYKER CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Sep 03 2014
Stryker to Present at Investor Conference Sep 03 2014
Zacks Industry Outlook Highlights: Zimmer Holdings, Medtronic, Covidien, Stryker and Smith & Nephew Aug 27 2014
Needham: Stryker Deal Not Dead For Smith & Nephew Aug 12 2014
Stryker Completes Acquisition of North American Assets of Small Bone Innovations, Inc. Aug 01 2014
Charles R. Kummeth, the President and CEO of Bio-Techne (TECH), Interviews with The Wall Street... Aug 01 2014
Smith & Nephew sees more sector deals, not under investor pressure Aug 01 2014
STRYKER CORP Financials Jul 31 2014
STRYKER CORP Files SEC form 10-Q, Quarterly Report Jul 24 2014
Intuitive Surgical rises after Q2 EPS, revenue beat expectations Jul 23 2014
Stryker appoints CEO Kevin Lobo as chairman Jul 22 2014
Stryker Announces Appointment of Kevin A. Lobo as Chairman of the Board of Directors Jul 22 2014
Stryker Declares a $0.305 Quarterly Dividend Jul 21 2014
Stryker Q2 Earnings Rise Marginally, Lag Estimates Jul 18 2014
Stryker to Host Analyst Meeting Jul 18 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK